Driehaus Capital (Michael Caldwell) initiated a new $17.5M position in Albemarle Corp (ALB), a lithium chemicals company — not a biotech or biopharma name. This appears to be a data misclassification; ALB has no meaningful drug pipeline, indication, or clinical catalyst relevant to a healthcare/biotech signal note. The two-fund convergence with Deerfield Management (a dedicated healthcare investor) warrants scrutiny, as Deerfield's ALB position may reflect a different thesis (e.g., specialty chemicals exposure) rather than biotech-specific conviction.

Unlock full AI analysis — 14-day free trial

Position Trend

Aug 14, 2025

0 funds

Nov 14, 2025

0 funds

Feb 17, 2026

0 funds

May 15, 2026

$17.5M

1 fund

+2867% total institutional value over 8 quarters

Short Interest

Short Shares

34K

Change

+61.2%

Days to Cover

0.4

Settlement

Feb 27, 2026

Short interest over 2 periods

Catalysts

No catalysts tracked.

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Position Details

Driehaus CapitalNEW POSITIONMay 15, 2026

Start free trialfor share counts, dollar values & AI analysis

8 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

PHGE1 fund ACAD1 fund AHCO1 fund ALEC1 fund ALNY1 fund ANNX1 fund ARWR1 fund SPRY1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Terms

Privacy

Disclaimer